市场调查报告书
商品编码
1463706
南美洲和中美洲直接面向消费者的基因测试市场预测至 2030 年 - 区域分析 - 按测试类型、技术和配销通路South & Central America Direct-to-Consumer Genetic Testing Market Forecast to 2030 - Regional Analysis - by Test Type, Technology, and Distribution Channel |
2022年,中南美洲直接面向消费者的基因检测市场价值为8,964万美元,预计2030年将达到3.4985亿美元;预计2022年至2030年CAGR为18.6%。
单核苷酸多态性 (SNP) 晶片的日益普及推动了南美洲和中美洲直接面向消费者的基因检测市场
近年来,随着科学知识的增加,从传统医学向个人化医学的典范稳步转变。这种转变归功于基因工程、单核苷酸多态性 (SNP) 基因分型以及微阵列和生物晶片技术的广泛采用。具有数十万个 SNP 的基因微阵列分析平台的引入将鼓励先进演算法的实施,以更公开地测试个体之间更隐蔽的家谱关係。此外,检测恶性肿瘤的需求也有所增加。在儿科领域,由于无需将 SNP 变异与大规模缺失杂交,週转时间短,因此产生了巨大的需求。因此,随着更多基因异常的检测和治疗,市场预计将会成长。
由于对技术先进和更复杂的 DTC 基因检测的持续需求,高效、准确的 SNP 晶片的需求不断增加。人们对 SNP 晶片的高度偏好可归因于它们能够测量剂量变化和 DNA 多态性,以及对癌症研究至关重要的各种应用,例如 SNP 微阵列分析。此外,对尽量减少 DTC 基因检测错误的需求日益增长,预计将推动 SNP 技术的采用,为市场成长提供机会。
南美洲和中美洲直接面向消费者的基因检测市场概述
南美洲和中美洲直接面向消费者的基因检测市场分为巴西、阿根廷以及南美洲和中美洲其他地区。该地区的市场受到遗传性疾病发病率迅速上升、老年人口不断增长、医疗保健系统的发展以及基因检测意识不断提高等因素的推动。遗传疾病以及慢性病盛行率的上升是推动巴西 DTC 基因检测市场成长的主要因素。例如,遗传性疾病和先天畸形共同构成巴西婴儿死亡的第二大常见原因。对个人化医疗的需求不断增长,疾病诊断新技术的引入,以及行业参与者对开发新诊断技术以提供更快、更准确的结果的关注,预计将成为有利于直接面向消费者的增长的其他值得注意的因素巴西的基因检测市场。随着科学家保证追踪有助于治疗肥胖和糖尿病等现代疾病流行的遗传特征,巴西的医学遗传学领域不断扩大。此外,巴西私人基因检测公司(尤其是提供亲子鑑定解决方案的公司)的数量正在增加。 2019年,巴西领先的基因检测实验室之一GENOMIKA与Veritas签署协议,将后者与预防医学和临床遗传学相关的全基因组和外显子组定序服务纳入其产品组合。
南美洲和中美洲直接面向消费者的基因检测市场收入及 2030 年预测(百万美元)
南美洲和中美洲直接面向消费者的基因检测市场区隔
南美洲和中美洲直接面向消费者的基因检测市场分为测试类型、技术、配销通路和国家。
根据测试类型,南美洲和中美洲直接面向消费者的基因测试市场分为血统测试、预测测试、营养基因组学测试、带因者测试等。 2022 年,血统测验细分市场占据最大份额。
从技术面来看,中南美洲直接面向消费者的基因检测市场分为全基因组定序、单核苷酸多态性晶片、标靶分析等。 2022年,单核苷酸多态性晶片领域占据最大份额。
根据配销通路,南美洲和中美洲直接面向消费者的基因检测市场分为线上和线下。 2022 年,线上细分市场占据了更大的份额。
根据国家/地区,南美洲和中美洲直接面向消费者的基因检测市场分为巴西、阿根廷以及南美洲和中美洲其他地区。 2022 年,巴西在南美洲和中美洲直接面向消费者的基因检测市场占据主导地位。
Ancestry Genomics Inc、Living DNA Ltd、23andMe Inc 和 Genetic Technologies Ltd 是南美洲和中美洲直接面向消费者基因检测市场的一些领先公司。
表中的内容
The South & Central America direct-to-consumer genetic testing market was valued at US$ 89.64 million in 2022 and is expected to reach US$ 349.85 million by 2030; it is estimated to grow at a CAGR of 18.6% from 2022 to 2030.
Growing Adoption of Single Nucleotide Polymorphism (SNP) Chips Fuels the South & Central America Direct-to-Consumer Genetic Testing Market
There has been a steady paradigm shift from traditional medicine to personalized medicine with increasing scientific knowledge in recent years. This shift is due to advances in genetic engineering, single nucleotide polymorphism (SNP) genotyping, and the high adoption of microarrays and biochip technologies. The introduction of genetic microarray analysis platforms with hundreds of thousands of SNPs will encourage the implementation of advanced algorithms to test for more secluded genealogical relationships more openly between individuals. In addition, the demand for detecting malignant tumors has also increased. In the pediatric field, the short turnaround time without the need to hybridize SNP variations to massive deletions has led to enormous demand. As a result, the market is expected to grow as more genetic abnormalities are detected and treated.
SNP chips with high efficiency and accuracy are witnessing an increase in demand due to the constant need for technologically advanced and more sophisticated DTC genetic testing. A high preference for SNP chips can be attributed to their ability to measure dosage changes and DNA polymorphism, along with various applications such as the SNP microarray analysis that are vital for cancer research. Furthermore, an increasing need to minimize errors in DTC genetic testing is expected to drive the adoption of SNP technology, thereby providing an opportunity for the market growth.
South & Central America Direct-to-Consumer Genetic Testing Market Overview
The South & Central America direct-to-consumer genetic testing market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in this region is driven by factors such as the burgeoning incidences of genetic disorders, the growing geriatric population, developments in healthcare systems, and rising awareness about genetic testing. The rising prevalence of the genetic disease, along with chronic illness, is the primary factor driving the growth of Brazil's DTC genetic testing market. For instance, genetic diseases and congenital abnormalities together represent the second most common cause of mortality among infants in Brazil. The growing demand for personalized medicines, introduction of novel technologies in disease diagnosis, and focus of industry players on developing new diagnostic techniques to provide faster results with high accuracy are expected to be other noteworthy factors to favor the growth of the direct-to-consumer genetic testing market in Brazil. The field of medical genetics has expanded in Brazil as scientists assure to track down genetic traits that will help to treat modern disease epidemics, such as obesity and diabetes. Moreover, the number of private genetic testing companies, particularly offering paternity testing solutions, is on the rise in Brazil. In 2019, GENOMIKA, one of the leading genetic testing laboratories in Brazil, signed an agreement with Veritas to incorporate the latter's Whole Genome and Exome Sequencing services associated with preventive medicine and clinical genetics into its portfolio.
South & Central America Direct-to-Consumer Genetic Testing Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Direct-to-Consumer Genetic Testing Market Segmentation
The South & Central America direct-to-consumer genetic testing market is segmented into test type, technology, distribution channel, and country.
Based on test type, the South & Central America direct-to-consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing market segment held the largest share in 2022.
In terms of technology, the South & Central America direct-to-consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held the largest share in 2022.
Based on distribution channel, the South & Central America direct-to-consumer genetic testing market is bifurcated into online , and offline. The online segment held a larger share in 2022.
Based on country, the South & Central America direct-to-consumer genetic testing market is segmented the Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America direct-to-consumer genetic testing market in 2022.
Ancestry Genomics Inc, Living DNA Ltd, 23andMe Inc, and Genetic Technologies Ltd are some of the leading companies operating in the South & Central America direct-to-consumer genetic testing market.
Table of Content